AUS
NZ
UK
CA
USA
IND
Highlights
- GeneTether enters exclusive licensing agreement for STS-201, targeting soft tissue sarcoma and other cancers.
- The company plans a private placement to raise up to C$500,000 to support the STS-201 program.
- John Rothman appointed as Chief Scientific Officer, bringing over 30 years of industry experience.
GeneTether Therapeutics Inc. has announced a significant development in its strategic growth with the entry into a binding term sheet with EGB Ventures. This agreement grants GeneTether an exclusive global license for EGB’s promising small molecule, STS-201, which has shown notable efficacy in treating soft tissue sarcoma and other types of cancers. The transaction represents a crucial step for GeneTether in advancing its mission to deliver impactful therapeutic solutions.
As part of the agreement, GeneTether plans to undertake a non-brokered private placement aimed at raising a minimum of C$250,000 and potentially up to C$500,000. This fundraising initiative will support the development and commercialization of STS-201, ensuring the company has the necessary resources to progress its innovative projects. The private placement is expected to consist of between 12.5 million and 25 million units, priced at C$0.02 each, which is a 17% premium over the 20-day volume-weighted average price.
The licensing agreement includes specific financial terms, where EGB will receive 12 million common shares of GeneTether, along with an upfront payment of US$150,000 and annual payments of US$150,000. Additionally, EGB will earn a 33% royalty on net sales of STS-201 and a share of any revenues from pediatric review vouchers that GeneTether may obtain.
To further enhance its leadership and scientific capabilities, GeneTether has appointed Dr. John Rothman as its Chief Scientific Officer. Dr. Rothman brings a wealth of experience to the role, having served in senior positions across several prominent pharmaceutical companies, including Roche and Schering-Plough. His extensive background in clinical drug development and product management will be invaluable as GeneTether navigates the complexities of bringing STS-201 to market.
The development of STS-201 is especially noteworthy due to its promising clinical history in Europe, where it has already demonstrated efficacy in treating soft tissue sarcoma. This asset provides GeneTether with a unique opportunity to unlock significant value and address unmet medical needs in oncology. The company's leadership, along with Dr. Rothman’s expertise, is optimistic about the potential for STS-201 to make a meaningful impact on patients’ lives.
The anticipated closing of both the licensing agreement and the private placement is contingent upon minority shareholder approval at GeneTether’s upcoming annual general and special meeting scheduled for December 12, 2024. If approved, these transactions are expected to close shortly thereafter.
As GeneTether moves forward with its initiatives, it will focus on advancing the STS-201 program, leveraging the funds from the private placement to enhance its research and development efforts. The company’s strategy aligns with the growing demand for effective cancer therapies, positioning it well within the competitive biopharmaceutical landscape.
